ES2139658T3 - Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica. - Google Patents

Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica.

Info

Publication number
ES2139658T3
ES2139658T3 ES93910775T ES93910775T ES2139658T3 ES 2139658 T3 ES2139658 T3 ES 2139658T3 ES 93910775 T ES93910775 T ES 93910775T ES 93910775 T ES93910775 T ES 93910775T ES 2139658 T3 ES2139658 T3 ES 2139658T3
Authority
ES
Spain
Prior art keywords
laci
treatment
inhibitor
lipoprotein
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93910775T
Other languages
English (en)
Inventor
Abla A Creasey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2139658T3 publication Critical patent/ES2139658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBE UN METODO PARA TRATAR LA SEPTICEMIA PROFILACTICA O TERAPEUTICAMENTE O EL SHOCK SEPTICO, EN DONDE UN INHIBIDOR DEL FACTOR DE TEJIDO SE ADMINISTRA A LOS PACIENTES SEPTICOS. ADICIONALMENTE, SE DESCRIBE UN METODO PARA TRATAR LA INFLAMACION, EN DONDE EL INHIBIDOR SE ADMINISTRA A LOS PACIENTES. EL INHIBIDOR ES CALIFICADO COMO INHIBIDOR DE COAGULACION ASOCIADO A UNA LIPOPROTEINA, O COMUNMENTE LACI. ESTE ES EL 38 KD Y TIENE 276 AMINOACIDOS. EL LACI SE HA MOSTRADO AHORA QUE ES UTIL PARA EL TRATAMIENTO DE LA SEPTICEMIA, LA INFLAMACION Y EL SHOCK SEPTICO.
ES93910775T 1992-06-01 1993-04-23 Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica. Expired - Lifetime ES2139658T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89194792A 1992-06-01 1992-06-01
US450593A 1993-01-13 1993-01-13

Publications (1)

Publication Number Publication Date
ES2139658T3 true ES2139658T3 (es) 2000-02-16

Family

ID=26673093

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93910775T Expired - Lifetime ES2139658T3 (es) 1992-06-01 1993-04-23 Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica.

Country Status (10)

Country Link
EP (1) EP0643585B1 (es)
JP (3) JP3957740B2 (es)
AT (1) ATE187648T1 (es)
CA (1) CA2136953C (es)
DE (1) DE69327314T2 (es)
DK (1) DK0643585T3 (es)
ES (1) ES2139658T3 (es)
GR (1) GR3032779T3 (es)
PT (1) PT643585E (es)
WO (1) WO1993024143A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
ATE239501T1 (de) * 1995-06-07 2003-05-15 Chiron Corp Regulierung der neutrophil elastase synthese und freisetzung
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
EP1361897A4 (en) * 2000-11-08 2004-10-13 Gen Hospital Corp METHODS FOR INHIBITING PAIN
US6939716B2 (en) 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
EA200400548A1 (ru) * 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
EP1654283B1 (en) 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
DE69327314T2 (de) 2000-04-13
CA2136953A1 (en) 1993-12-09
JP3957740B2 (ja) 2007-08-15
JPH07507300A (ja) 1995-08-10
GR3032779T3 (en) 2000-06-30
JP2004210801A (ja) 2004-07-29
DE69327314D1 (de) 2000-01-20
ATE187648T1 (de) 2000-01-15
CA2136953C (en) 2006-10-31
DK0643585T3 (da) 2000-05-08
WO1993024143A1 (en) 1993-12-09
EP0643585B1 (en) 1999-12-15
PT643585E (pt) 2000-05-31
EP0643585A1 (en) 1995-03-22
JP2007137901A (ja) 2007-06-07

Similar Documents

Publication Publication Date Title
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
ES2139658T3 (es) Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica.
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
ES2093695T3 (es) Composicion para el tratamiento de trastornos inflamatorios del intestino.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
HU9301978D0 (en) Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin
DE59007531D1 (de) Verwendung des Wirkstoffs Azelastin zur Bekämpfung von Psoriasis-Erkrankungen.
ES2107470T3 (es) Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal.
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
ES2123004T3 (es) Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
RU93033683A (ru) Способ лечения язвенной болезни двенадцатиперстной кишки
HUP9800810A2 (hu) Kombinációs terápia emberi immunhiány-vírusos (HIV) ferőzés kezelésére
ES2101100T3 (es) Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura.
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
RU2020953C1 (ru) Способ лечения тромбоокклюзионных поражений сосудов
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU97109107A (ru) Способ лечения гнойных ран
RU93008439A (ru) Способ лечения хронического гнойного среднего отита
RU93042345A (ru) Способ лечения повреждения суставов и их последствия
GR880100839A (el) Αλας τρομε?αμίνης του 1-με?ύλ-Β-ΟΞΟ-Α-(φαινυλοκαρβομουλό)-2-πυρρολοπροπιονιτριλίου.
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита
RU94010776A (ru) Лекарственная форма для электрофореза гнойных ран
RU94022014A (ru) Способ лечения путем непрерывного выделения органического нитрата

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643585

Country of ref document: ES